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SUMMARY
In lower eukaryotes, Sir2 serves as a histone deacetylase and is implicated in chromatin silencing, longevity,
and genome stability. Here we mutated the Sirt1 gene, a homolog of yeast Sir2, in mice to study its function.
We show that a majority of SIRT1 null embryos die between E9.5 and E14.5, displaying altered histone mod-
ification, impaired DNA damage response, and reduced ability to repair DNA damage. We demonstrate that
Sirt1+/;p53+/mice develop tumors inmultiple tissues, whereas activation of SIRT1 by resveratrol treatment
reduces tumorigenesis. Finally, we show that many human cancers exhibit reduced levels of SIRT1 com-
pared to normal controls. Thus, SIRT1 may act as a tumor suppressor through its role in DNA damage re-
sponse and genome integrity.INTRODUCTION
In Saccharomyces cerevisiae, Sir2maintains genomic integrity in
multiple ways. As a NAD+-dependent histone deacetylase, Sir2
has been reported to regulate chromatin silencing (Blander and
Guarente, 2004; Guarente, 2000). Sir2 is required for establish-
ment and maintenance of telomeric heterochromatin (Denu,
2003; Gasser and Cockell, 2001). When overexpressed, Sir2
has been shown to extend life span in both budding yeast and
Drosophila (reviewed in Blander and Guarente, 2004; Saunders
and Verdin, 2007). Previous reports have also demonstrated
that Sir2 is involved in DNA damage repair (McAinsh et al.,
1999; Mills et al., 1999; Tsukamoto et al., 1997). A protein com-
plex containing Sir2 has been reported to translocate to DNA
double-strand breaks (McAinsh et al., 1999; Mills et al., 1999;
Tsukamoto et al., 1997). In addition, Sir2-deficient yeast strainsdisplay defects in the nonhomologous end-joining (NHEJ) path-
way of DNA double-strand break repair (Guarente, 2000).
The mammalian sirtuin family consists of seven NAD+-depen-
dent type III histone and protein deacetylases (SIRT1–7). These
proteins share a catalytic domain of about 275 amino acids
and are primarily localized in the nucleus (SIRT1, 6, and 7), mito-
chondria (SIRT3, 4, and 5), and cytoplasm (SIRT2), respectively
(reviewed in Blander and Guarente, 2004; Saunders and Verdin,
2007). It has been shown that SIRT2 plays a role in the mitotic
checkpoint to arrest cells if DNA damage is detected. SIRT3
enhances acetyl-CoA production by deacetylating acetyl-CoA
synthetase 2. SIRT4 represses glutamate dehydrogenase to
suppress insulin signaling through its ADP-ribosylase activity.
SIRT6 has both ADP-ribosylase and deacetylase activity and
plays a role in base excision repair. SIRT7 is involved in transcrip-
tion of rRNA genes through its interaction with RNA polymerase ISIGNIFICANCE
SIRT1 has diverse roles in various biological processes, including caloric restriction, which causes changes in glucose me-
tabolism and life span. The role of SIRT1 in cancer is currently under debate due to recent discrepant findings. It is known
that caloric restriction, which activates SIRT1, extends life span and inhibits tumorigenesis. On the other hand, SIRT1 de-
acetylates p53 to decrease its activity. It has therefore been hypothesized that increased SIRT1 activity, although it extends
life span, may elevate cancer risk. Here we demonstrate that SIRT1 plays an important role in DNA damage response and
genome integrity by maintaining proper chromatin structure and DNA damage repair foci formation. We further show that
SIRT1 serves as a tumor suppressor in mice and in some types of human cancers.
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(reviewed in Baur et al., 2006; Haigis and Guarente, 2006; Saun-
ders and Verdin, 2007; Vaquero et al., 2007). The most extensive
study, however, has been directed toward the functions of
SIRT1, the founding member of this sirtuin family and the mam-
malian ortholog of yeast Sir2. SIRT1 modifies histones through
deacetylation of K9 in histone H3 (H3K9) and K16 in histone H4
(H4K16) and also deacetylates many nonhistone proteins that
are involved in cell growth, apoptosis, neuronal protection, ad-
aptation to caloric restriction, organ metabolism and function,
cellular senescence, and tumorigenesis (Baur et al., 2006; Haigis
and Guarente, 2006; Saunders and Verdin, 2007; Vaquero et al.,
2007). One of themost notable targets of SIRT1 is p53, which plays
a critical role in cell-cycle checkpoint regulation, apoptosis, and tu-
mor suppression. It has been shown that overexpression of SIRT1
deacetylates p53, leading to the suppression of p53 activity (Chen
et al., 2005; Kim et al., 2008; Zhao et al., 2008).
Figure 1. Deletion of SIRT1 Results in Embryonic Lethality
(A) E9.5 wild-type (+/+) and SIRT1 null (/) embryos. Both mutant embryos
are arrested at early E8, and one (middle) has not finished turning yet.
(B) E11.25 +/+ and / embryos. Both / embryos are smaller, with abnor-
mal shape of the head or lack of hindlimb bud (arrow).
(C) E12.5 +/+ and / embryos.
(D) E18.5 +/+ and +/ embryos.
(E) DAPI staining of heart and brain histological sections of E11.5 +/+ and /
embryos.
(F–H) Expression of Bcl-2 and survivin in E11.5 +/+ and/ embryos revealed
by standard PCR (F), real-time RT-PCR (average ± SD) (G), and western blot
analysis (H).
Scale bars = 500 mm in (A)–(D) and 50 mm in (E).
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SIRT1 Is a Haploinsufficient Tumor SuppressorFunctions of SIRT1 have also been studied at the whole-
organism level using targeted gene disruption. However,
SIRT1 mutant mice generated by different targeting strategies
exhibit distinct phenotypes (Cheng et al., 2003). Approximately
50% of mice carrying a truncation mutation through a targeted
replacement of exons 5 and 6 with a hygromycin gene died at
early postnatal stages, while the remaining mice were smaller
but survived to adulthood (McBurney et al., 2003). No global de-
fects in gene silencing in these mutant mice were detected
(McBurney et al., 2003). On the other hand, the majority (90%)
of SIRT1 mutant animals carrying a deletion of exon 4 died peri-
natally, exhibiting developmental defects of the retina and heart,
and the remaining 10% of these mutants were still surviving at
weaning (Cheng et al., 2003). Because SIRT1 mutant cells in
these animals displayed p53 hyperacetylation upon DNA dam-
age and increased ionizing radiation-induced apoptosis in thy-
mocytes, it was suspected that the SIRT1 deficiency might ac-
tivate p53, leading to the lethality of mutant mice (Cheng et al.,
2003). While these studies revealed involvement of SIRT1 in
mammalian development, they were not able to recapitulate
yeast Sir2 functions in gene silencing, DNA damage repair,
and longevity. Of note, the role of SIRT1 in tumorigenesis is cur-
rently under debate due to some recent discrepancies. For ex-
ample, the observation that SIRT1 deacetylates p53 to de-
crease its activity has led to the hypothesis that increased
SIRT1 activity may elevate cancer risk in mammals (Chen
et al., 2005). On the other hand, it was recently demonstrated
that increased expression of SIRT1 reduces colon cancer for-
mation in the APCmin/+ mouse model (Firestein et al., 2008). Fur-
thermore, resveratrol, which activates SIRT1 (Howitz et al.,
2003), exhibits chemopreventive activity against various can-
cers including leukemia (Li et al., 2007), DMBA-induced mam-
mary tumors in rats (Whitsett et al., 2006), skin cancer (Aziz
et al., 2005), and prostate cancer (Harper et al., 2007).
In this study, we created a SIRT1 mutant mouse model and
studied the role of SIRT1 in DNA damage response and tumori-
genesis. Our data provide strong evidence that mammalian
SIRT1 plays an important role in DNA damage repair, genomic
integrity, and inhibition of tumorigenesis.
RESULTS
Generation of SIRT1 Mutant Mice
The Sirt1 gene was mutated by deleting exons 5 and 6, which
encode a part of the catalytic domain (see Figures S1A–S1D
available online). Western blot analysis using an antibody to
the N terminus of SIRT1 revealed that there was no truncated
protein in embryos homozygous for the mutation (Figure S1D),
suggesting that the SIRT1 mutation we created is a candidate
null mutation.
Previous investigations showed that mice carrying mutations
of SIRT1 died at perinatal stages up to several months into
adulthood (Cheng et al., 2003; McBurney et al., 2003). How-
ever, we found that embryos homozygous for the mutation
(Sirt1/) began to die at embryonic day 9.5 (E9.5) (Figure 1A;
Table S1). Abnormal Sirt1/ embryos were also found at later
stages of development (Figures 1B and 1C). There was a signif-
icant decrease in Sirt1/ embryos at E14.5–E16.5, and no
homozygous embryos were found at E17.5–E18.5 among
Cancer Cell 14, 312–323, October 7, 2008 ª2008 Elsevier Inc. 313
Cancer Cell
SIRT1 Is a Haploinsufficient Tumor Suppressor69 embryos dissected. Some Sirt1+/ embryos also exhibited
exencephaly (Figure 1D). After analyzing 442 offspring, we
found that the survival rate of homozygous SIRT1 mutant
mice was about 1% in a 129SvEv/FVB background and 9.3%
in a 129SvEv/FVB/Black Swiss background (Table S1). These
observations indicated that our Sirt1/ mice exhibited more
severe phenotypes than those reported previously (Cheng
et al., 2003; McBurney et al., 2003).
SIRT1 Deficiency Results in Accumulation of Cells
in the Early Phase of Mitosis
Inorder tounderstand thephenotype,we further analyzedSirt1/
mice during embryonic development. Most E10.5–E12.5 Sirt1/
embryos were abnormally small, and DAPI staining showed nu-
clear fragmentation and cell death (Figure 1E). However, these
dead cells were negative for TUNEL assay, suggesting that the
cell deathmight not be causedby typical apoptosis. Further anal-
ysis of the embryos demonstrated that some antiapoptotic
genes, such as Bcl-2 and survivin, were elevated in SIRT1 null
embryos (Figures 1F–1H), which might protect Sirt1/ cells
fromapoptosis.Wenext analyzed cell proliferation usingBrdU la-
beling (Figures S2A–S2C) and phosphorylated histone H3 stain-
ing, a marker for cells at the early phase of mitosis (Figures
S2D–S2F). Sirt1/ embryos had 15%–20%more BrdU labeling
at E10.5 and E11.5 than control embryos, but the labeling re-
turned to normal levels at E12.5 (Figure S2C). During the same
time period, Sirt1/ embryos had 1.5- to 2-fold more cells that
were positive for phosphorylated histone H3 compared to wild-
type controls (Figure S2F). Histone H3 phosphorylation occurs
in prophase, which is normally for a short duration. The marked
Figure 2. Deletion of SIRT1 Causes Chromosome
Abnormality
(Aa) DAPI staining of tissue sections showing abnormal mitotic
features in an E10.5 Sirt1/ embryo.
(Ab) Data were collected from three pairs of embryos; 200
mitotic phases from each embryo were counted.
(Ba–Bc) Chromosome spreads from E9.5 embryos showing
normal spread (Ba), aneuploid and abnormal structures or
broken chromosomes (arrow, Bb), and less condensed chro-
mosomes (Bc).
(Bd) Chromosome spreads from nine pairs of embryos were
prepared, and all of the spreads from each individual embryo
were counted.
(Ca) SIRT1 mutant MEFs display incompletely condensed and
lagging chromosomes (arrow) and uneven chromosome seg-
regation under a relative normal spindle (a-tubulin staining).
(Cb) Summary of data from (Ca).
Data are presented as average ± SD. Scale bars = 10 mm in (A)
and (B) and 20 mm in (C).
increase of phosphorylated histone H3 suggests
that SIRT1 deficiency causes abnormal accumula-
tion of cells in the early phases of mitosis.
SIRT1 Deficiency Causes Incomplete
Chromosome Condensation and
Chromosome Instability
To investigate this further, we examined mitotic
chromosome morphology in the embryos. Staining
tissue sections of E10.5 embryoswithDAPI indicated thatSirt1/
embryos exhibited chromosome abnormalities characterized by
chromosome lagging and unequal segregation (Figure 2A).
These abnormal chromosome structures were found in 37% of
Sirt1/ cells, compared with less than 5% of wild-type cells.
Chromosome spreads prepared from E9.5 embryos showed
that about 37% of Sirt1/ cells were aneuploid and displayed
a variety of structural aberrations, such as broken and decon-
densed chromosomes (Figure 2B). Analysis of chromosome
spreads prepared from Sirt1/ mouse embryonic fibroblasts
(MEFs) detected similar abnormalities (data not shown). Next,
we analyzed metaphase chromosomes in cells that were not
treated with colcemid using an antibody against a-tubulin to-
gether with DAPI staining. In wild-type cells, chromosomes at
metaphase are highly condensed and aligned along with the
metaphase plate. However, many Sirt1/ MEFs at metaphase
contained a partially condensed and disorganized chromosomal
mass that was associated with a relatively normal spindle (Fig-
ure 2C). Chromosome aneuploidy and breaks could conceivably
originate from the continuous division of these mutant cells.
SIRT1 Deficiency Impairs Heterochromatin Formation
It is known that SIRT1 deacetylates K16 of histone H4 and K9 of
histone H3 in yeast and in in vitro-cultured mammalian cells
(Vaquero et al., 2007). Western blotting with antibodies against
Ac-K9 and Ac-K16 revealed increased levels of both H3 Ac-K9
and H4 Ac-K16 in Sirt1/MEFs (Figures 3A and 3B), and recon-
stitution of SIRT1 in these cells reduced their acetylation
(Figure 3C). Because histone acetylation plays a major role in
chromosome condensation, we hypothesized that the alteration
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in histone modification in Sirt1/ embryos might be a cause of
the chromosomal abnormalities. To investigate this, we per-
formed immunofluorescence staining on brain sections of E11
embryos. Our data showed that SIRT1 mutants contained
a much higher level of H3 Ac-K9 (Figure 3D), while no significant
alteration of H4 Ac-K16 was detected (data not shown). This
finding was confirmed by western blot analysis (Figure 3E), dem-
onstrating that mammalian SIRT1 is capable of modifying his-
tones in vivo, although in the early embryos, SIRT1 seemed to
have stronger effects on acetylation of histone H3K9 than his-
tone H4K16.
Increased acetylation of K9 on histones impairs its trimethyla-
tion level, thus affecting heterochromatin formation. To verify this
point, an antibody against trimethylated K9 ((me)3-K9) was ap-
plied to brain sections from E11 embryos (Figure 3F). Sirt1/
mutant brain contained much less trimethylated K9 than control
brain. Similarly, a distinct reduction in trimethylated K9 foci was
also detected in Sirt1/ MEFs (Figure 3G). A function of trime-
thylated K9 is to recruit heterochromatin protein 1 (HP1a).
HP1a contains a chromatin modification organizer motif that
binds to histonemethyltransferases in order to establish a closed
chromatin configuration that represses transcription. We did not
Figure 3. SIRT1 Deficiency Alters Epigenetic Modification of Chro-
matin
(A and B) Western blot analysis showing increased histone H3K9 (A) and
H4K16 (B) levels in Sirt1/ (/) MEFs.
(C) Reconstitution of SIRT1 in / MEFs reduces histone Ac-K9 and Ac-K16
levels.
(D and E) Ac-K9 immunofluorescence staining of brain in E11 embryos (D).
/ embryos displayed much more Ac-K9 staining than +/+ embryos, which
is confirmed by western blot analysis (E).
(F) (me)3-K9 immunofluorescence staining of E11 brain. / embryos display
much less (me)3-K9 staining than +/+ embryos.
(G) In MEFs, loss of SIRT1 impairs distribution of HP1a. Deletion of SIRT1
causes diffused localization compared with punctuated foci in +/+ embryos.
Scale bars = 100 mm in (D) and (F) and 10 mm in (G).
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diffusely present, and consequently, there was no colocalization
between trimethylated K9 and HP1a. The impaired heterochro-
matin formation accounts for reduced chromosome condensa-
tion, which could be a cause of genomic instability.
SIRT1 Deficiency Results in Cell-Cycle Abnormalities
and Impaired DNA Damage Repair
Genetic instability could also result from cell-cycle checkpoint
defects and impaired DNA damage repair (Deng, 2006). To com-
prehensively understand the effect of SIRT1 deficiency, we stud-
ied cell-cycle checkpoints and DNA damage repair. Our analysis
failed to detect obvious abnormalities in the G2/M cell-cycle
checkpoint in Sirt1/ cells (data not shown). When cells were
treated with 10 Gy of g irradiation (IR), both wild-type (WT) and
Sirt1/ MEFs showed a similar reduction (60%) of cells in S
phase, suggesting that Sirt1/ cells have a normal G1/S cell-
cycle checkpoint (Figure 4A). However, we found that Sirt1/
MEFs did not respond to lower doses of g irradiation
(Figure 4B), revealing G1/S checkpoint defects under these con-
ditions. Thus, the large-scale DNA damage induced by a high
dose of IR is sufficient to activate redundant checkpoint signal-
ing cascades in Sirt1/ cells. Of note, H2AX mutant and Nijme-
gen breakage syndrome (NBS) mutant cells showed a similar re-
sponse, i.e., exhibiting G1/S and/or G2/M defects at low but not
high doses of IR (Antoccia et al., 1997; Ferguson and Alt, 2001).
Next, we assessed DNA damage repair ability in Sirt1/
cells. To investigate this, MEFs were transfected with a microho-
mologous DNA damage repair reporter, the pGL2-Luc vector,
linearized with either HindIII or EcoRI. Forty-eight hours post-
transfection, the cells were collected and luciferase activity
was quantified. With HindIII digestion, there was no significant
difference in Luc activity between wild-type and Sirt1/ cells.
In contrast, upon EcoRI digestion, the wild-type cells were able
to recover about 70% of Luc activity while Sirt1/ cells recov-
ered only 42% (Figure 4C). Because EcoRI cuts within the coding
sequence of the luciferase gene, the restoration of luciferase ac-
tivity therefore requires the precise rejoining of the short protrud-
ing ends, which involves microhomologous DNA damage repair.
The reduced Luc activity in SIRT1 mutant cells indicates that the
absence of SIRT1 reduces the microhomologous DNA damage
repair ability. On the other hand, because HindIII cuts within
the linker region between the SV40 promoter and the Luc coding
sequence, the restoration of luciferase activity does not require
precise end joining. These data indicate that the absence of
SIRT1 does not interfere with end ligation if such a ligation
does not require a precise end rejoining.
To further illustrate the effect of impaired DNA damage repair,
we used the comet assay, an extremely sensitive assay to detect
DNA damage at the single-cell level. We found that Sirt1/ cells
contained, on average, an 2-fold longer comet tail (12.44 mM)
than wild-type cells (6.74 mM) when quantitatively measured
2 hr post 5 Gy g irradiation (Figures 4D and 4E). We also per-
formed a radiosensitivity assay using a serially increased dosage
of g irradiation (Figure 4F). We found that Sirt1/ cells were sig-
nificantly more sensitive to radioactivity compared to wild-type
cells at doses up to 5 Gy. These data are consistent with the find-
ing that Sirt1/ cells have impaired DNA damage repair. Be-
cause g irradiation primarily causes DNA double-strand breaks,
Cancer Cell 14, 312–323, October 7, 2008 ª2008 Elsevier Inc. 315
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duces single-strand breaks. We found that Sirt1/ cells were
also more sensitive to UV radiation than wild-type cells
(Figure 4G), suggesting that SIRT1 may be also involved in other
types of DNA damage repair, such as base excision repair.
Defective DNA Damage Repair Correlates
with Decreased gH2AX Foci Formation
To investigate the mechanistic base of impaired DNA damage
repair, we stained the cells with an antibody to gH2AX, which
is a DNA damage sensor and helps maintain genome integrity
(Celeste et al., 2003). Upon g irradiation, Sirt1/ cells showed
markedly decreased gH2AX foci compared with WT cells
(Figure 5A). There are at least two possible factors resulting in
a decrease in gH2AX foci formation: lack of initial phosphoryla-
tion or lack of retention of phosphorylation. To distinguish be-
Figure 4. Deletion of SIRT1 Leads to Impaired DNA Damage Repair
and Radiation Sensitivity
(A and B) SIRT1 deletion caused impaired response to a low dosage of g irra-
diation (B), but not to high dosage (A), when assessed by BrdU incorporation
24 hr after irradiation.
(C) SIRT1 mutant cells exhibit impaired microhomologous recombination as
revealed in cells transfected with a pGL2-Luc vector that was linearized with
either HindIII or EcoRI.
(D and E) Comet assay reveals that Sirt1/ (/) cells are incapable of
efficiently repairing g irradiation-induced double-strand DNA damage. Comet
assay was performed 2 hr after MEFs received 5 Gy of g irradiation. Scale bar
in (D) = 100 mm.
(F and G) / MEFs are more sensitive than +/+ controls as revealed by g
irradiation (F) and ultraviolet radiation (G). *p < 0.05.
All data were obtained by analyzing at least six pairs of individual MEFs at
passage 1. Data are presented as average ± SD.
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then followed gH2AX foci formation during a time course. We
found that the initial gH2AX foci were significantly fewer in
Sirt1/ MEFs (20 foci/cell) than in WT cells (48 foci/cell). After
15 min of IR, both Sirt1/ and WT cells maintained a similar in-
crease at 30 and 60 min after treatment (Figure 5B). This obser-
vation indicates that SIRT1 deficiency reduces initial H2AX phos-
phorylation while the ability of retaining H2AX phosphorylation is
not affected. The differential levels of gH2AX were also detected
by western blot analysis (Figure 5C). To confirm this, we treated
WT cells with trichostatin A (TSA, an inhibitor of class I and II his-
tone deacetylases) and/or nicotinamide (NIC, an inhibitor of
class III histone deacetylases) followed by western blot with an
antibody to gH2AX. These data confirmed that the inhibition of
class III, but not class I and II, histone deacetylases inhibited
H2AX phosphorylation (Figure 5D). Indeed, inhibition of class I
and II histone deacetylases increased levels of gH2AX, even in
the presence of nicotinamide. These data suggest that class
I/II and class III histone deacetylases have opposing roles in
H2AX phosphorylation and that the negative effect of class I/II
histone deacetylases could supersede the positive effect of
class III histone deacetylases if both deacetylases are inhibited.
Toassesswhether the reducedgH2AX foci formation is adirect
consequence of SIRT1 loss, we transfected Sirt1/ cells with
a SIRT1 expression vector. Our data indicated that the SIRT1-
reconstituted Sirt1/ cells contained relatively equal numbers
of gH2AX foci compared with WT controls upon 3 Gy treatment
(Figure 5E). Since gH2AX foci formation serves as a sensor for
DNA damage (Kobayashi, 2004; Paull et al., 2000), impairment
at this step may affect the downstream response to DNA dam-
age. To investigate this, we examined foci formation of Rad51,
BRCA1, and NBS1 following g irradiation. Our data revealed
marked reduction in nuclear foci formation of these proteins in
SIRT1 mutant mice compared with WT MEFs (Figures 5F–5H).
Of note, our western blot analysis did not reveal changes in pro-
tein levels (Figure 5I), suggesting that these proteins cannot be
efficiently recruited to DNA damage sites in SIRT1 mutant cells.
H2AX can be phosphorylated by ataxia telangiectasiamutated
(ATM) upon g irradiation. Therefore, we studied ATM phosphor-
ylation and its downstream substrates. Immunofluorescence
staining with an antibody to phosphorylated ATM (pi-ATM) did
not reveal significant changes in pi-ATM foci in Sirt1/ MEFs
post g irradiation (Figure S3A). Western blots showed that after
g irradiation, levels of phosphorylated CHK2 and p53(Ser20)
showed no obvious difference between WT and Sirt1/ MEFs
(Figures S3B and S3C). Altogether, these observations suggest
that SIRT1 deficiency impairs DNA damage response and that
this effect is independent of the ATM/CHK2/p53 pathway.
Haploinsufficiency of SIRT1 Facilitates Tumorigenesis
Genetic instability is a major cause of tumor formation (Deng,
2001). However, a role of SIRT1 in tumorigenesis could not bede-
termined due to embryonic lethality. Since the absence of SIRT1
increases p53 activity, it has been suspected that embryonic
lethality of SIRT1 mutant embryos is due at least in part
to p53 activation (Cheng et al., 2003). To test this, we introduced
a p53 null mutation into SIRT1 mutant mice. We failed to
obtain Sirt1/;p53/ mice among 429 pups generated from
interbreeding between Sirt1+/;p53+/ mice, although five
(5/429 = 1.2%) Sirt1/;p53+/ mice were obtained (Table S2).
Thus, absence of p53 did not rescue the embryonic lethality as-
sociated with SIRT1 deficiency, suggesting that the embryonic
lethality associated with SIRT1 deficiency is not caused by p53
activation.
Sirt1+/;p53+/mice were healthy; however, they started to de-
velop spontaneous tumors fromabout 5monthsof age, and tumor
incidence reached about 76% by 20 months of age, while only 2
out of 21 Sirt1+/mice and 3 out of 22 p53+/mice developed tu-
mors during the same period of time (Figure 6A). The tumors that
occurred in Sirt1+/;p53+/ mice were primarily sarcomas
(45.9%), lymphomas (35%), teratomas (21.6%), and carcinomas
(16.2%) (Figure 6B; Figure S4). Chromosome spreads from pri-
mary tumors (11 tumors) showed extensive aneuploidy (83.8%)
and chromosomal aberrations, notably translocations, chromo-
some breaks, deletions, and dicentric chromosomes (Figure 6C).
Spectral karyotyping (SKY) analysis was performed on meta-
phase spreads derived from early passages of two primary tu-
mors, 841A (mammary gland carcinoma) and 785S (hemangio-
sarcoma) (Figure 6D). SKY analyses on metaphase spreads
derived from primary cells at early passages of tumor 785S
showed a variety of clonal aberrations. The nonreciprocal trans-
Figure 5. SIRT1 Deficiency Impairs gH2AX Foci For-
mation
(A) gH2AX foci formation is reduced 2 hr after 3 Gy irradiation.
(B) Time course showing reduced initiation of gH2AX foci in
SIRT1 mutant cells. Six pairs of MEFs at passage 1 were irra-
diated with 3 Gy, and gH2AX foci number was counted in each
individual cell. One hundred of each type ofMEFwere counted
in both untreated and 3 Gy-irradiated cells. *p < 0.05. Data are
presented as average ± SD.
(C)Western blot showing significantly reduced gH2AX levels in
Sirt1/ (/) compared to +/+ cells.
(D) Nicotinamide (NIC) treatment diminished gH2AX levels in
Sirt1+/+ cells.
(E) Transfection of a vector carrying wild-type SIRT1 (pUSE-
SIRT1, Upstate), but not a GFP control, restored gH2AX foci
formation in / cells. SIRT1 expression levels by western
blot analysis are shown at right.
(F–H) Immunofluorescence staining of BRCA1 (F), NBS1 (G),
and Rad51 (H) in +/+ versus/MEFs. Nuclear foci formation
is reduced in the mutant cells.
(I) Western blots showing no alteration in total protein levels of
BRCA1, NBS1, Rad51, and H2AX.
Scale bars = 100 mm in (A) and (E) and 10 mm in (F)–(H).
location involved chromosome 13 and chromo-
some 2, giving rise to a T(13;2) translocation
(30%), and a complex translocation involving an
insertion of chromosome 4 into chromosome 10
resulted in a T(10;4;10) translocation or T(4;10)
(30%) (Figure 6D; Figure S5A). Dicentric chromo-
somes were observed involving two copies of
chromosome 6 in a Dic(6;6) (40%) (Figure 6D; Fig-
ure S5B). Numerous chromosome breaks produc-
ing both acentric and centric chromosome frag-
ments from chromosomes 1, 2, 4, 8, 10, and 19
were identified (Figure 6D). Furthermore, 50% of
the spreads lost chromosome 10, 70% lost chro-
mosome 7, and 60% lost chromosome 12. Exten-
sive chromosome abnormality was observed in cells from
841A carcinomas (Figure S5A). All of these clonal aberrations
recorded from 841A and 785S metaphase spreads were con-
firmed by fluorescence in situ hybridization (FISH) (Figures
S5B–S5E). Both of these tumors showed random gains and los-
ses of whole chromosomes. However, a consistent and recur-
rent gain of chromosome 3 (>90%) and loss of chromosome 7
(55%) was observed in spreads from both tumors. Taken
together, these results demonstrate that SIRT1 deficiency se-
verely impairs genome integrity and/or stability and could be
one of the causes for spontaneous tumorigenesis in Sirt1 and
p53 double-heterozygous animals.
RT-PCR analysis of tumor tissues demonstrated that 73%
(11 of 15) of the tumors examined lost p53 expression and
27% (4 of 15) of the tumors lost SIRT1 expression (Figure S6A).
Southern blot showed that 77% (10 of 13) exhibited loss of
heterozygosity (LOH) of p53 (Figure S6B). Next, we examined
SIRT1 protein levels in tumor tissues by western blot analysis
and found that 44% (7 of 16) of the tumors had no or low levels
of SIRT1 (Figure S6C). Meanwhile, Southern blot analysis re-
vealed that 18% (3 of 17) of the tumors showed LOH of Sirt1
(Figure S6D).
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The observation that the majority of tumors maintained one
wild-type allele of Sirt1 suggests that SIRT1 serves as a haploid
tumor suppressor gene. To test this, we investigated whether
this Sirt1 allele is functional by using resveratrol, an activator of
SIRT1 (Howitz et al., 2003). Female Sirt1+/;p53+/ mice were
randomized into two groups. One group (n = 10) was provided
with resveratrol-supplemented drinking water (7.5 mg/ml), while
the other group was provided with drinking water either with
(n = 10) or without (n = 16) carrier (DMSO) supplement. The treat-
ment started at 2 months of age and lasted for 9 months. During
this period, 21 out of 26 (80%) of the mice in the control group
developed tumors; in contrast, only 3 out of 10 (30%) of the
mice in the resveratrol-treated group developed tumors (1
hemangiosarcoma and 2 thymic lymphomas). We noticed that
the partial inhibition of tumor formation was also correlated
with a delay in tumor onset, i.e., the first tumor occurred in the
control group at 5 months of age, while the first tumor in the
treated group occurred at 7 months of age (Figure 6E).
Next, we investigated whether the reduced tumor formation
was due to SIRT1 activation. We first examined expression of
several SIRT1 downstream genes, including G6pase, Pepck,
and Pgc-1a (Lagouge et al., 2006; Rodgers et al., 2005). We
Figure 6. SIRT1 Deficiency Causes Genomic Instabil-
ity and Tumor Formation
(A) Tumor-freecurveofdifferentgenotypesofmice, includingWT
(n = 18), p53+/ (n = 12), Sirt1+/ (n = 37), and Sirt1+/;p53+/
(n = 49).
(B) Types and percentages of tumors developed in
Sirt1+/;p53+/ mice.
(C) Chromosome spread from a mammary tumor. Regardless
of the tumor type, general events observed include aneu-
ploidy, numerous structural chromosomal aberrations, and
premature chromosome segregation. Arrows point to abnor-
mal chromosomes. Scale bar = 10 mm.
(D) Spectral karyotyping (SKY) analysis of metaphase spreads
from a primary tumor showing nonreciprocal translocation
(T(13;2)(C3-D1)), complex nonreciprocal translocation
(T(10;4;10)), dicentric chromosomes, and a variety of chromo-
somal fragments from chromosomes 1, 2, 4, 8, 10, and 19,
respectively.
(E) Resveratrol treatment reduces tumor incidence in
Sirt1+/;p53+/mice. The resveratrol-treated group consisted
of 10 female mice. The control group contained 10 DMSO-
treated and 16 untreated female mice. Log rank test: p < 0.01.
(F) Resveratrol treatment causes altered expression of several
known downstream genes of SIRT1. Data are presented as
average ± SD.
(G) Western blot analysis showing that all three tumors devel-
oped in the resveratrol-treated Sirt1+/;p53+/ mice lost
SIRT1 expression, while only one out of four tumors in the
mock-treated mice lost SIRT1 expression.
detected significantly increased levels of these
genes in resveratrol-treated compared with control
Sirt1+/;p53+/ mice (Figure 6F), suggesting that
the remaining copy of Sirt1 in Sirt1+/;p53+/
mice is activated. We showed earlier that 18% of
tumors exhibited LOH of Sirt1 and up to 44% of tu-
mors had no or low levels of SIRT1. Resveratrol
should not inhibit growth of tumors if they are
negative for SIRT1. To see if this was the case,
we performedwestern blot analysis for SIRT1 expression in these
tumors.We found thatoneof four tumorsdeveloped in theDMSO-
treated group lost SIRT1 protein, while all three tumors developed
in resveratrol-treated mice did not contain SIRT1 protein
(Figure6G). The lossofSIRT1 in these tumorsexplainswhy resver-
atrol did not inhibit their formation.However, the cause for the loss
of SIRT1 protein in these tumors remains elusive, as no LOH of
Sirt1 was detected by Southern blot analysis (Figure S6E).
Expression Levels of SIRT1 in Clinical Cancer Samples
Our view that SIRT1 may serve as a tumor suppressor seems, at
least on the surface, contradictory to current reports that SIRT1 is
expressed in certain primary tumors and cell lines at high levels.
This includes prostate cancer (Huffman et al., 2007), acute mye-
loid leukemia (Bradbury et al., 2005), nonmelanoma skin cancers
(Hida et al., 2007), and colon cancer (Stunkel et al., 2007). To
investigate this, we compared SIRT1 levels in the available data
sets; surprisingly, we found that SIRT1 levels are actually lower
in many cancers than normal tissues, including glioblastoma,
bladder carcinoma, prostate carcinoma, and various forms of
ovarian cancers (Figure S7). To provide our own assessment
for this issue, we performed the following three experiments.
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First, we performed western blot analysis of eight types of
tumors, including lung, breast, colon, stomach, liver, bladder,
skin, and thyroid. Our data revealed reduced SIRT1 levels in
breast cancerandhepaticcell carcinoma (HCC)compared to their
normal controls, while slightly increased (thyroid) or unchanged
(lung, colon, stomach, bladder, and skin) SIRT1 levels were de-
tected inother tumors (Figure7A).Next,weperformed tissuearray
analysis to compare SIRT1 protein levels between 44 breast can-
cers and 25 normal breast tissue samples. Our data detected sig-
nificantly higher levels of SIRT1 in all normal breast tissuesamples
than in cancers (Figures 7B and 7C). We also analyzed SIRT1
expression levels in microarray data from 263 HCC samples.
Our data indicated that SIRT1was reduced 2-fold in 42 of 263 tu-
mors, increased 2-fold in 4 tumors, and unchanged in the remain-
ing 217 tumors (Figures 7D and 7E). To provide a validation of the
microarray data, we randomly picked 10 HCC samples that
showed reduced levels of SIRT1 and performed real-time RT-
PCR on these samples. Our data revealed reduction of SIRT1 in
all of the samples comparedwith their normal controls (Figure 7F).
Figure 7. SIRT1 Gene Expression in Human
Clinical Cancers
(A) Levels of SIRT1 in eight different cancers and
their normal controls measured by western blot
analysis.
(B and C) SIRT1 protein levels in 44 breast cancers
and 25 normal breast tissue samplesmeasured by
tissue array.
(B) Levels of SIRT1 staining were classified as
negative (No), low, medium, high, or very high.
(C) Immunohistochemical images. The boxed
regions (enlarged below) show high levels of
SIRT1 in normal epithelium and lowered levels in
cancers. Scale bars = 100 mm.
(D) SIRT1 expression levels inmicroarray data from
263 hepatic cell carcinoma (HCC) samples,
presented as raw log2 ratio of tumors to paired
noncancerous liver tissues (T/N) using a previously
described data set (GEO accession number
GSE5975) (Yamashita et al., 2008). Each bar
representsan individual case, andpseudocolors in-
dicate transcript levelsbelow,equal to,orabove the
mean (green, black, and red, respectively). Missing
data are denoted in gray. The scale represents the
gene expression ratios from5 to +5 in log2 scale.
(E) HCC cases categorized by relative SIRT1 ex-
pression levels based on geometric fold changes.
(F) Real-time RT-PCR data (average ± SD) from ten
pairs of samples.
Altogether, the observations that
Sirt1+/;p53+/ mice develop tumors in
multiple tissues and that SIRT1 levels
are reduced in many human cancers pro-
vide strong evidence that SIRT1 may
function as a tumor suppressor in mice
and in some human tissues.
DISCUSSION
We have shown that the majority of our
Sirt1/ mice died at E9.5–E14.5. This
phenotype is more severe than that of the other two SIRT1 mu-
tant mice reported previously (Cheng et al., 2003; McBurney
et al., 2003). A number of possible reasons could account for
this difference. First, all of these mutant mice were studied in dif-
ferent genetic backgrounds. The mice used by McBurney et al.
(2003) were generated using R1 embryonic stem (ES) cells de-
rived from embryos of 129Sv 3 129Sv-CP (Nagy et al., 1993).
Homozygous SIRT1 mutant mice on the 129Sv-CP background
were smaller and invariably died within 1 month after birth, while
on the 129/CD1mixed background, the mutants more often sur-
vived to adulthood, although their stature was smaller than that
of their littermates (McBurney et al., 2003). The mice used by
Cheng et al. (2003) and our mice were generated using TC1 ES
cells derived from embryos of 129SvEv mice (Deng et al.,
1996). On the 129SvEv/C57BL/6 background, about 90%of mu-
tant mice died at perinatal or early postnatal stages, and most of
the remaining mutant animals died about 3 months after birth
(Cheng et al., 2003). In our study, the majority of the Sirt1/ (de-
letion of exons 5 and 6) mice died at middle stages of embryonic
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and 9.3% on the 129SvEv/FVB/Black Swiss background sur-
vived to adulthood. These observations indicate that the genetic
background has a profound effect on the phenotypes of all three
SIRT1 mutant strains. Furthermore, these mutant mice also con-
tained distinct targeted mutations, i.e., a replacement of exons 5
and 6 with a hygromycin gene (McBurney et al., 2003), a deletion
of exon 4 (Cheng et al., 2003), or a deletion of exons 5 and 6 (this
study) using the Cre/loxP-mediated approach. The potential
effect of these different mutations on phenotypes of SIRT1
mutant mice is currently unclear, as no truncated SIRT1 protein
was observed in these mutant mice.
Absence of SIRT1 Causes Genetic Instability
What is the cause (or causes) of the early lethality of SIRT1 mu-
tant embryos? Our data revealed several major defects that may
contribute to embryonic lethality. Mutant embryos analyzed at
E10.5–E12.5 exhibited an altered pattern of histonemodification,
i.e., reduced levels of (me)3-K9 and increased acetylation of
H3K9. These data provide in vivo evidence for the function of
SIRT1 in histone modification previously found in yeast and
cultured cells (Vaquero et al., 2007). A consequence of altered
acetylation is reduced chromosome condensation, which may
account for why mutant embryos contained 1.5- to 2-fold more
cells in the prophase of mitosis. In addition, we also detected
loosely compacted chromosomes in themetaphase. This abnor-
mality may interfere with normal progression of the remaining
phases of mitosis and consequently lead to the formation of
chromosome bridges, chromosome breaks, unequal chromo-
some segregation, and aneuploidy. The extensive genetic insta-
bility may be a primary reason for the death of mutant embryos.
In yeast, Sir2 plays a role in DNA damage repair (McAinsh
et al., 1999; Mills et al., 1999; Tsukamoto et al., 1997). This func-
tion, however, has not been demonstrated in its mammalian
homolog, SIRT1. Our study detected impaired microhomology-
mediated DNA damage repair and double-strand break repair
in SIRT1 mutant cells. The marked reduction of gH2AX, Rad51,
BRCA1, and NBS1 foci formation upon DNA damage could
serve as a cause of the reduced efficiency of DNA damage
repair. Furthermore, recent studies have indicated that SIRT1
acetylates Ku70 (Jeong et al., 2007) and NBS1 (Yuan et al.,
2007). All of these proteins are involved in the regulation of cellu-
lar response to DNA double-strand breaks and/or DNA damage
repair, although the involvement of other factors needs to be
investigated.
SIRT1 Is a Haploinsufficient Tumor Suppressor Gene
The role of SIRT1 in cancer is currently under debate. SIRT1 is
overexpressed in several types of human cancers (Bradbury
et al., 2005; Hida et al., 2007; Huffman et al., 2007; Stunkel
et al., 2007). However, it is unclear whether SIRT1 simply serves
as a marker for tumorigenesis or indeed affects tumor growth
(Lim, 2006). The regulation of the cellular response to DNA dam-
age andmaintenance of genetic stability may indicate that SIRT1
inhibits tumor formation (Stunkel et al., 2007). Consistent with
this, it has recently been demonstrated that increased expres-
sion of SIRT1 reduces colon cancer formation in the APCmin/+
mouse model (Firestein et al., 2008). On the other hand, data
also uncover a role of SIRT1 in deacetylating p53, leading to
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shown that inhibition of SIRT1 using a specific inhibitor causes
p53 hyperacetylation and increases p53-dependent transcrip-
tion activity (Lain et al., 2008).
On the other hand, previous studies revealed that p53 can be
activated by targeted mutation of several genes, such as Brca1
(Xu et al., 2001), leading to embryonic lethality, which can be
suppressed by introduction of a p53 null mutation. Therefore,
we reasoned that if the lethality of SIRT1 mutant mice is attrib-
uted to activation of p53, the simultaneous mutation of p53
should have some impact on Sirt1 phenotypes. To test whether
embryonic lethality was caused by p53 activation, we crossed
SIRT1 mutant mice with p53 null mice (Donehower et al., 1992).
Our data detected no rescue of embryonic lethality, suggesting
that activation of p53 in SIRT1mutant mice is not amajo r reason
for the embryonic lethality.
Moreover, our analysis of public data sets revealed that SIRT1
expression levels are lower than in their normal controls in five
types of tumors, including glioblastoma, bladder carcinoma,
male germcell tumors, prostate carcinoma, and ovarian cancers.
Our own analysis of 44 breast cancers and 263 HCCs also re-
vealed markedly reduced expression of SIRT1 in these tumors.
These data suggest that SIRT1 may not serve as an oncogene;
instead, it may act as a tumor suppressor in these tissues. Con-
sistent with this notion, we demonstrated that Sirt1+/;p53+/
mice develop cancers in multiple tissues. Southern blot and
western blot analyses indicated that most tumors still maintained
one wild-type allele of Sirt1, suggesting that a proper dose of
SIRT1 is critical for inhibiting tumorigenesis. We further showed
that activation of SIRT1 by resveratrol can partially inhibit tumor
formation. It has been demonstrated that resveratrol has chemo-
preventive activity against various cancers including leukemia,
DMBA-induced mammary tumors in rats, skin cancer, and pros-
tate cancer (reviewed in Aggarwal et al., 2004; Delmas et al.,
2006). We have also found that resveratrol treatment activates
SIRT1 and significantly inhibits growth of BRCA1-associated
cancers (R.-H.W. and C.-X.D., unpublished data).
In summary, our analysis of SIRT1 mutant mice has yielded in-
sights regarding the functions of SIRT1. SIRT1 plays an impor-
tant role in maintenance of heterochromatin structure through
deacetylation of histones in vivo. SIRT1 also has an important
role inmodulating gH2AX, BRCA1, Rad51, and NBS1 foci forma-
tion, which are involved in DNA damage repair and the cell-cycle
checkpoint. Finally, our observations that impaired SIRT1 func-
tion results in tumor formation on a p53 null background and
that activation of SIRT1 by resveratrol reduces tumorigenesis
provide compelling evidence that SIRT1 serves as a tumor
suppressor gene in mice and some human cancers.
EXPERIMENTAL PROCEDURES
Mating and Genotyping of Mice
Chimericmice, obtained by injecting targetedSirt1+/EScells into blastocysts,
were mated with NIH Black Swiss or C57BL6 females to screen for germline
transmission. Male mice bearing germline transmission were mated with fe-
male FVB EII-Cre mice (Lakso et al., 1996) to generate complete deletion of
Sirt1 exons 5 and 6. The animals were genotyped by either Southern blot or
PCR using primer 1, 50-TCCTTGCCACAGTCACTCAC-30; primer 2, 50-ACAG
TCCCATTCCCATACC-30; and primer 3, 50-CATCTAAACTTTGTTGGCTGC-30.
Primers 1 and 3 are located within intron 4 and amplify the wild-type allele
(660 bp). Primer 2 is located within exon 7; the combination of primers 1 and
2 amplifies the deleted allele (716 bp). All experiments were approved by the
Institutional Animal Care and Use Committee of the National Institute of Diabe-
tes and Digestive and Kidney Diseases.
Proliferation Assays on Embryos
Sirt1+/ mice were mated to generate wild-type (+/+) and mutant (/) em-
bryos. At E10.5, E11.5, and E12.5, females were injected with BrdU. Females
were euthanized 2 hr postinjection, and embryos were collected, fixed with
formalin, and genotyped. Five micrometer sections from paraffin-embedded
samples were processed either with BrdU staining (BrdU labeling kit, Zymed)
or staining with antibody against phosphorylated histone H3 at Ser10 (pi-H3,
Upstate). BrdU- and pi-H3-positive signals were counted from 20 different
areas and analyzed by Student’s t test.
Chromosome Spreads from Embryos, Primary Tumors, and MEFs
Chromosome spreads from embryos were performed as described previously
(Deng and Xu, 2004; Shen et al., 1998). Briefly, embryos were incubated with
100 ng/ml colcemid for 2 hr. The hypotonic treatment was carried out for
20 min at room temperature in 0.56% KCl. The embryos were transferred to
methanol:acetic acid (3:1) for fixation. The embryos were then disaggregated
under a dissection microscope in 60% acetic acid. The disaggregated
embryos were spun down, suspended in methanol:acetic acid, and dropped
onto slides. All chromosome spreads were stained with Giemsa, and chromo-
some number and morphology were assessed under a Leica microscope with
a 1003 objective and Olympus camera with MagnaFire software (Optronics,
purchased from Olympus).
Immunofluorescence Staining
Methanol-fixed MEFs were stained with antibodies against BRCA1 (Turner
et al., 2004); Rad51 (Ab-1, Calbiochem); NBS1 (C-19, Santa Cruz); a-tubulin
(Sigma); and gH2AX, (me)3-K9 of histone H3, and HP1a (Upstate) using
methods described previously (Wang et al., 2004). Images were acquired us-
ing either a 633 or 1003 lens on an Olympus X81 microscope and processed
with Slidebox software. Deparaffinized brain sections from embryos were
cooked with Retriever (Cat. 62700-10, Electronic Microscopy Science) in
buffer A (citrate buffer, pH 5.0) followed by staining with antibodies against
H3 Ac-K9 and/or H4 Ac-K16 (Upstate).
Western Blotting
Western blot was carried out by Li-Cor (Lincoln, NE, USA) with antibodies
against BRCA1 (Turner et al., 2004), Rad51 (Ab-1, Calbiochem), NBS1 (C-19,
Santa Cruz), H2AX (Cat. 07-627, Upstate), gH2AX (Cat. 05-636, Upstate),
CHK2 (Cat. 611571, Becton Dickinson), p53(Ser20) (Cat. 9287, Cell Signaling),
p53 (DO-1, Becton Dickinson), SIRT1 (Cat. 07-131, Upstate), Bcl-2 (Sc-783,
Santa Cruz), survivin (NB500-201, Novus), histone H3 (Cat. 06-755, Upstate),
H3 Ac-K9 (Cat. 07-352, Upstate), histone H4 (Cat. 07-108, Upstate), H4 Ac-
K16 (Cat. 06-762, Upstate), b-actin (A5441, Sigma), and a-tubulin (T6074,
Sigma).
FACS Analysis of g-Irradiated MEFs
MEFs at passage 1 were irradiated with different dosages and labeled with
BrdU for 24 hr. The cells were fixed with 70% ethanol, stained with anti-
BrdU antibodies (Becton Dickinson), and then counterstained with 25 mg/ml
propidium iodide. The stained cells were analyzed with a FACSCalibur (Becton
Dickinson). The percentage of BrdU-positive cells in the control group was set
as 100%.
Comet Assay
Primary MEFs at passage 1 were irradiated with 5 Gy and incubated for 2 hr.
Cells were then collected and processed per the manufacturer’s protocol
(CometAssay 4250-050-K, Trevigen).
RT-PCR
Total RNA was isolated from cells or tissues with STAT-60 following the man-
ufacturer’s protocol (Tel-Test, Inc.). cDNA was synthesized with Cells-
to-cDNA II (Ambion, Inc.). Primer sequences were as follows:
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CTTTGCCACTGCAAATGG-30; mouse SIRT1: forward 50-TTGTGAAGCTGTT
CGTGGAG-30, reverse 50-GGCGTGGAGGTTTTTCAGTA-30; mouse survivin:
forward 50-GTTTGAGTCGTCTTGGCGGAG-30, reverse 50-GTCTCCTTCTCTA
AGATCCTG-30; mouse Bcl-2: forward 50-ATACCTGGGCCACAAGTGAG-30,
reverse 50-TCTTGTAGGCACCTGCTCCT-30; mouse p53: forward 50-CACGT
ACTCTCCTCCCCTCA-30; reverse 50-CTTCTGTACGGCGGTCTCTC-30.
Resveratrol Treatment
Resveratrol (Cat. 60512A, AKSci) treatment was carried out on 36 female
Sirt1+/;p53+/ mice. Starting at 2 months of age, one group of mice (n = 10)
was treated with resveratrol (7.5 mg/ml)-supplemented drinking water daily;
another group (n = 10) was treated with carrier (DMSO, 0.015%)-supple-
mented drinking water daily. The drinking water was kept away from light
and changed every 3 days. Resveratrol treatment was maintained for 9
months. The remaining 16 mice were untreated.
Spectral Karyotyping Analysis
SKY analysis was performed as described previously (Padilla-Nash et al.,
2006). FISH was performed on metaphase spreads from tumors 785S and
841A by hybridization with whole-chromosome paints against selected target
chromosomes that appeared clonally in two or more instances out of ten
spreads from SKY analyses.
Clinical Specimens
Tumor and matched normal sample lysates were purchased from Protein Bio-
technologies (http://www.proteinbiotechnologies.com/). Twenty microgram
aliquots of protein lysates were loaded on gels for western blot analysis. West-
ern blotting was performed with both SIRT1 and tubulin antibodies. The tissue
array of breast cancer samples was purchased from US Biomax (Cat.
BR1002). Immunohistochemical staining against SIRT1 (Cat. 07-131, Upstate)
was carried out with a HistoMouse-SP (AEC) kit (Cat. 95-9544, Zymed). cDNA
microarray analysis for 263 HCCs was described previously (Yamashita et al.,
2008). Validation of microarray data was carried out by qRT-PCR using the
following primers:
SIRT1 forward 50-GCAGATTAGTAGGCGGCTTG-30, reverse 50-TCATCCT
CCATGGGTTCTTC-30; 18S forward 50-CGGCTACCACATCCAAGGAA-30, re-
verse 50-GCTGGAATTACCGCGGCT-30.
Use of human tissues was approved by the NIH Office of Human Subjects
Research.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, two tables, and seven figures and can be foundwith this
article online at http://www.cancercell.org/cgi/content/full/14/4/312/DC1/.
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